Reported Feb 22, 2017 · Terminated

Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc…

Actavis Inc.

Moderate riskThis product could cause temporary or reversible health problems — stop using it.

What you should do

Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.

Firm contact: Actavis Inc · 400 Interpace Pkwy · Parsippany, NJ · 07054-1120

Is this the product you have?

  • Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4
Lot codes and dates
    • Lot #: 3134201
    • 3134202
    • Exp. 06/30/17
    • 3134319
    • Exp. 05/31/17
    • 3135246
    • Exp. 07/31/17
    • 3135247
    • 3136781
    • Exp. 08/31/17
    • 3136782
    • Exp. 09/30/17
    • 3136903
    • 3136904
    • Exp.10/31/17
    • 3138250
    • Exp. 07/31/17
    • 3138968
    • Exp. 08/31/17
    • 3140000
    • Exp. 09/30/17
Amount recalled
499320 units

Where it was sold

  • Nationwide

Why it was recalled

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

This product could cause temporary or reversible health problems — stop using it.

Want the full recall guide?

The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.

Free recall alerts

Get alerted about new Actavis Inc. recalls

One email when a matching recall is published. No account, no cost, unsubscribe in one click.

Where this came from

Source: U.S. Food & Drug Administration (openFDA)

Read the FDA (openFDA drug enforcement) notice

Notice updated Mar 13, 2018 · Data as of Sep 19, 5:52 PM UTC

RecallNow is not a government agency. Every fact on this page is published by the FDA, USDA or CPSC and links back to their notice.